Meseguer Barros, Carmen MarinaAlzueta Isturiz, NataliaSainz de Rozas Aparicio, RitaVizcaíno, Rafael AguilellaLópez Esteban, LauraAnaya Ordóñez, SoniaLekue Alkorta, ItxasneMartín Suances, SalvadoraJiménez Arce, Jorge IgnacioFernández Vicente, MaiteBorrego Izquierdo, YolandaPrieto Sánchez, RaquelCasado Casuso, SilviaMadridejos, RosaVerde, Carmen MarquinaTomás Sanz, RosaOro Fernández, MaríaGallardo Borge, SaraLázaro López, EvaPina Gadea, María BelénPereira Pía, MercedesMaestre-Sánchez, María VictoriaRibes-Murillo, EstherGómez de Oña, ConstanzaMaría Jesús Lallana, ÁlvarezCelaya Lecea, ConcepciónPrado Prieto, María AnaAranguez Ruiz, AranzazuOlmo Quintana, VicenteVillén Romero, NoemíPayá Giner, CarolinaLloret Callejo, AngelesFernández Ferreiro, AlvaroBasagoiti Carreño, BlancaIglesias Iglesias, Ana AureliaMartín Alonso, AntonioDíez Alcántara, AnaMarco Tejón, EstherLestón Vázquez, MartaAriza Copado, Mª ÁngelesAparicio Cueva, MartaEscudero Vilaplana, BelénNicieza, MarisaPicazo Sanchiz, GraciaSilva Riádigos, Genma MaríaSánchez, Lucía JamartGarcía Álvarez, ÁngelGarcía Bonilla, AntonioHerrero Delicado, RafaelArroyo Pineda, Virginiade la Hija, BelénTroncoso Mariño, AmeliaTofiño González, IsabelMateu García, Mónica SusanaGarcía Vázquez, PabloPérez Martín, JoaquínFernández-Urrusuno, Rocío2025-01-072025-01-072021-08-252079-6382https://hdl.handle.net/10668/24734The aim of this study was to know the prevalence and severity of COVID-19 in patients treated with long-term macrolides and to describe the factors associated with worse outcomes. A cross-sectional study was conducted in Primary Care setting. Patients with macrolides dispensed continuously from 1 October 2019 to 31 March 2020, were considered. Main outcome: diagnosis of coronavirus disease-19 (COVID-19). Secondary outcomes: symptoms, severity, characteristics of patients, comorbidities, concomitant treatments. A total of 3057 patients met the inclusion criteria. Median age: 73 (64-81) years; 55% were men; 62% smokers/ex-smokers; 56% obese/overweight. Overall, 95% of patients had chronic respiratory diseases and four comorbidities as a median. Prevalence of COVID-19: 4.8%. This was in accordance with official data during the first wave of the pandemic. The most common symptoms were respiratory: shortness of breath, cough, and pneumonia. Additionally, 53% percent of patients had mild/moderate symptoms, 28% required hospital admission, and 19% died with COVID-19. The percentage of patients hospitalized and deaths were 2.6 and 5.8 times higher, respectively, in the COVID-19 group (penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/COVID-19SARS-CoV-2ambulatory careazithromycinlong-term treatmentmacrolidesoutpatientsresearch article34572621open access10.3390/antibiotics10091039PMC8468207https://www.mdpi.com/2079-6382/10/9/1039/pdf?version=1629905605https://pmc.ncbi.nlm.nih.gov/articles/PMC8468207/pdf